Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study

Yoshikawa, Katsuhiro; Ishida, Mitsuaki; Yanai, Hirotsugu; Tsuta, Koji; Sekimoto, Mitsugu; Sugie, Tomoharu

doi:10.1371/journal.pone.0242563

Cited by 13 publications

(35 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the previous study, we analysed the relationship between adipophilin expression, a lipid droplet-associated protein, and the clinicopathological features of TNBC patients. The content of this study did not overlap with that of our previous one [ 20 ].…”

Section: Methodsmentioning

confidence: 87%

“…Patients with special types of invasive carcinoma were excluded from the study, because each special type of carcinoma has unique clinicopathological features; hence, 61 patients with TNBC comprised this study cohort. The present cohort was fundamentally the same as that of our previous study [ 20 ]. In the previous study, we analysed the relationship between adipophilin expression, a lipid droplet-associated protein, and the clinicopathological features of TNBC patients.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Cancer-associated fibroblasts (CAFs) are some of the most abundant components of the tumour microenvironment. A recent study suggested that in some cancers, CAFs express programmed death ligand 1 (PD-L1), which can act as a prognostic marker. The aim of this study was to investigate the clinicopathological significance of CAF PD-L1 expression in patients with triple-negative breast cancer (TNBC) and to identify the most suitable primary antibody for immunostaining for CAF PD-L1. Methods Immunohistochemical staining (primary antibodies of 73–10, SP142, and E1L3N) and tissue microarrays were used to analyse the expression profiles of PD-L1 in CAF in 61 patients with TNBC who underwent surgery. Overall survival (OS) was compared based on CAF PD-L1 expression, and the risk factors for OS were analysed. The relationship between clinicopathological parameters and survival was also examined. Results Thirty-four (55.7%) patients were positive for CAF PD-L1 (73–10) expression. Compared with CAF PD-L1 negativity, there was a significant correlation between CAF PD-L1 positivity and better OS (p = 0.029). CAF PD-L1 expression, evaluated using SP-142 or E1L3N, did not correlate with OS. CAF PD-L1-positivity (73–10) correlated significantly with better prognosis in multivariate analyses (hazard ratio: 0.198; 95% confidence interval: 0.044–0.891; p = 0.035). Conclusions CAF PD-L1 expression is a novel marker for a better prognosis of patients with TNBC, and the 73–10 assay may be suitable for immunostaining CAF PD-L1.

show abstract

Section: Methodsmentioning

confidence: 87%

Section: Methodsmentioning

confidence: 99%

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…We selected 165 consecutive patients with TNBC who underwent surgical resection at the Department of Surgery, Kansai Medical University Hospital (Osaka, Japan), between January 2006 and December 2018. Patients administered neoadjuvant chemotherapy or those with a special type of invasive carcinoma were excluded, because chemotherapy may influence the expression of PD-L1 and/or CD155, and may affect prognosis [ 20 ]. Eventually, 61 patients with TNBC were included in this study.…”

Section: Methodsmentioning

confidence: 99%

“…Eventually, 61 patients with TNBC were included in this study. The patient cohort was fundamentally the same as that of our previous study [ 20 ], in which we analyzed the relationship between adipophilin expression, a lipid droplet-associated protein, and the clinicopathological features of patients with TNBC. The contents of this paper, analyzing the significance of CD155, an immune checkpoint protein, in patients with TNBC, do not overlap with those of our previous study [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail. Methods Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73–10 assays), was also examined. Results CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73–10 assay did not show a correlation (p = 0.115). Using the 73–10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively). Conclusions CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy.

show abstract

“…In total, 62 patients with TNBC were included in the study cohort. This study cohort was fundamentally the same as that used in our previous studies [27][28][29]. In a previous study, we analyzed the relationship between adipophilin expression, a lipid droplet-associated protein, and the clinicopathological features of patients with TNBC [27].…”

Section: Patient Selectionmentioning

confidence: 99%

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit from immunotherapy is a critical issue. Several assays have been used to evaluate PD-L1 expression, and a few studies comparing PD-L1 expression using various primary antibodies in TNBC tissues have been reported. However, the expression profiles of the PD-L1 using the 73–10 assay have not yet been analyzed in TNBC tissues. Methods We analyzed the PD-L1 immunohistochemical profiles of 62 women with TNBC using the 73–10, SP142 (companion diagnostic for atezolizumab), and E1L3N assays. PD-L1 expression on immune cells (ICs) and tumor cells (TCs) was also evaluated, and PD-L1 positivity was defined as a PD-L1-expressing ICs or TCs ≥ 1%. Results The expression rates of PD-L1 were 79.0%, 67.7%, and 46.8% on ICs, and 17.7%, 6.5%, and 12.9% on TCs using the 73–10, SP142, and E1L3N assays, respectively. The concordance rates between the 73–10 and SP142 assays were 85.5% (on ICs) and 88.7% (on TCs), respectively, and substantial agreement on ICs (coefficient 0.634) and moderate agreement (coefficient 0.485) on TCs were noted. Sample age and tumor diameter did not influence the ratio of PD-L1 expression among the assays. Conclusions The positive rate on ICs and TCs of the 73–10 assay was higher than that of the SP 142 and E1L3N assays. Although substantial agreement on ICs and moderate agreement on TCs between the 73–10 and SP142 assays was noted in the present cohort, further studies are needed to clarify the PD-L1 expression status using various primary antibodies in a larger patient population. This would lead to the establishment of an effective evaluation method to assess the predictive value of anti-PD-L1 immunotherapy.

show abstract

Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study

Cited by 13 publications

References 26 publications

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer

Contact Info

Product

Resources

About